Ophthalmic Business News

A study highlighted the growing role of industry funding in ophthalmology research, with a 203% increase between 2014 and 2020.

Ocuphire Pharma and FamyGen Life Sciences have entered into a global licensing agreement that will allow Famy to fund and commercialize the development of Nyxol eye drops in the U.S. as well as globally, according to a press release.

Viatris Inc. announced that it will be acquiring both Oyster Point Pharma and Famy Life Sciences, which will help the company meet its goal of creating an ophthalmology franchise, according to a press release.

The 2022 Digital Ophthalmic Society meeting was the first ever eye care conference to be held in a space station, or at least that is what it looked like.

When I first heard about people in medicine using the metaverse, I was the biggest skeptic.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Rob Thornhill, CEO of Centricity Vision, discusses two of the company’s new cataract surgery products.

Iveric Bio has submitted the first part of a new drug application to the FDA for a rolling review of Zimura for the treatment of geographic atrophy secondary to age-related macular degeneration.

With support from Nova Eye Medical, a group of surgeons has launched a registry that will capture real-world data on canaloplasty procedures performed with the iTrack and iTrack Advance devices.

Vabysmo achieved positive safety and efficacy results in two global phase 3 studies investigating its use for macular edema due to branch and central retinal vein occlusion, according to a press release from Genentech.

UBX1325 met safety and efficacy endpoints at 24 weeks in the phase 2 BEHOLD study in patients with diabetic macular edema, according to a press release from Unity Biotechnology.